Associations - ER mutation

ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials
ER mutation ER mutation	Breast Cancer Breast Cancer	palbociclib Resistant: B - Late Trials
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	exemestane Resistant: B - Late Trials
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant Sensitive: B - Late Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	Aromatase inhibitor + palbociclib Resistant: B - Late Trials
ER mutation ER mutation	Breast Cancer Breast Cancer	fulvestrant Sensitive: C2 – Inclusion Criteria
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials
ER mutation ER mutation	Breast Cancer Breast Cancer	venetoclax Sensitive: C3 – Early Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	enobosarm Sensitive: C3 – Early Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	SAR439859 Sensitive: C3 – Early Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK6 inhibitor Resistant: C3 – Early Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK4 inhibitor Resistant: C3 – Early Trials
ER mutation ER mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib Resistant: C3 – Early Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	RAD1901 Sensitive: C3 – Early Trials
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	bevacizumab + paclitaxel Sensitive: C3 – Early Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	G1T48 Sensitive: C4 – Case Studies
ER mutation ER mutation	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	RAD1901 Sensitive: D – Preclinical